Valproate (Epilim) - Important Safety Information from Sanofi-Aventis Ireland Limited as approved by the HPRA (15.09.23)

Notice type: 3rd Party Publications

Date: 15/09/2023




Problem Or Issue:

Important Safety Information from Sanofi-Aventis Ireland Limited regarding Valproate (Epilim) – ongoing review of potential risk of neurodevelopmental disorders in children of fathers treated with valproate in the three months prior to conception.


Important Safety Information – Valproate (Epilim)

 




« Back